Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncogene licenses cancer detection technology to Bayer for inclusion on Technicon Immuno 1 analyzer.

This article was originally published in The Gray Sheet

Executive Summary

ONCOGENE SCIENCE CANCER DIAGNOSTIC R&D DEAL WITH BAYER provides a fully automated serum-based analyzer, Bayer's Technicon Immuno 1, for Oncogene's in vitro cancer detection technology. The deal replaces a development pact with Becton Dickinson that had been in place since 1984. In September, Oncogene chose not to renew the deal with BD because the firm does not offer an automated immunoassay system.

You may also be interested in...

Bayer's $11 Mil. Oncogene Purchase Adds Oncology Diagnostics Stable

Bayer's acquisition of OSI Pharmaceuticals' diagnostic business builds on the firms' collaborative efforts to run OSI's HER-2/neu breast cancer assay on Bayer's Technicon Immuno I automated immunoassay.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts